文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Comment on "Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis".

作者信息

Kellermayer Richard, Lewindon Peter, Buness Cynthia, Tabibian James, Johnson Kevin, Shah Shamita, Dulai Parambir, Ali Ahmad H, Shah Ayesha, Holtmann Gerald, Winter Harland S

机构信息

Division of Pediatric Gastroenterology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, 6621 Fannin Street, Houston, TX 77030-3411, USA.

USDA/ARS Children's Nutrition Research Center, Houston, TX, USA.

出版信息

Therap Adv Gastroenterol. 2025 Apr 21;18:17562848251332453. doi: 10.1177/17562848251332453. eCollection 2025.

DOI:10.1177/17562848251332453
PMID:40297210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12035255/
Abstract
摘要

相似文献

[1]
Comment on "Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis".

Therap Adv Gastroenterol. 2025-4-21

[2]
How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?

Indian J Gastroenterol. 2022-10

[3]
Authors' comment on: effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.

Therap Adv Gastroenterol. 2025-3-24

[4]
Vancomycin Therapy for Induction and Maintenance of Remission in a Patient with Refractory Ulcerative Colitis and Primary Sclerosing Cholangitis: A Case Report and Literature Review.

Case Rep Gastroenterol. 2025-5-6

[5]
Outcomes of oral vancomycin therapy in children with atypical ulcerative colitis with or without confirmed primary sclerosing cholangitis: a real-world observational study.

BMJ Open Gastroenterol. 2025-2-12

[6]
Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.

Therap Adv Gastroenterol. 2025-1-9

[7]
The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review.

Inflamm Bowel Dis. 2025-7-7

[8]
Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.

J Pediatr Gastroenterol Nutr. 2008-7

[9]
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic Signatures.

J Crohns Colitis. 2025-2-4

[10]
Management of Primary Sclerosing Cholangitis and Extraintestinal Disorders in Patients With Ileal Pouches: A Systematic Review.

Dis Colon Rectum. 2024-6-1

本文引用的文献

[1]
Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.

Therap Adv Gastroenterol. 2025-1-9

[2]
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic Signatures.

J Crohns Colitis. 2025-2-4

[3]
Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune-mediated liver injury.

Hepatology. 2024-5-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索